Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OSHA Standards Could Prompt Federal, State Safety Needle Bill Passage

This article was originally published in The Gray Sheet

Executive Summary

Release of OSHA's bloodborne pathogen standards will not preclude Congress from addressing legislation in the next session that would require hospitals to use safety needle devices, Capitol Hill staffers say.

You may also be interested in...



Needlestick Prevention Claims Require Support Of Clinical Data, Panel Says

Clinical data demonstrating efficacy of a sharps injury prevention device should be submitted to FDA in support of any claim, suggestion, or hint that the device reduces the incidence of sharps injury, FDA's General Hospital and Personal Use Devises Advisory Panel concluded.

California Safe Needle Law Could Presage Efforts By More States, OSHA

The implementation of legislation in California designed to reduce the incidence of accidental needlesticks among health care workers may prompt additional states to enact laws mandating the use of needles and other sharps designed with protective safety features.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel